Formulation, Characterization of Baclofen Nanoliposome Vesicles by Nylon-66 Nanofiber Membranes, and Evaluation of Their Effect on Lactate Dehydrogenase and Creatine Kinase Enzymes as Inhibitors

Background: Formulation of baclofen in lipid-based nanoparticles may be helpful to overcome its difficulties in order to reach the site of action in the central nervous system. This study reports production, characterization, and evaluation of baclofen nanoliposome vesicles (BLV 2 ). This way makes drugs more stable for delivery systems design. Methods: Baclofen nanoliposomes were prepare by the method of wetting thin films, vesicles in the solution filtered by passing them through nylon 6.6 fibers to improve homogeneity and ensure the passage of small unilamellar lipid vesicles. The formation of the vesicles was tested by spectrophotometric assay Fourier transform infrared spectroscopy (FT-IR), dynamic light scattering (DLS), and morphology method field emission scanning electron microscopy (FESEM). In addition in vitro release assay, inhibition activity for lactate dehydrogenase (LDH), creatine kinase (CK) enzymes, and half maximal inhibitory concentration 50 were measured. Results: Baclofen nanoliposome vesicles were demonstrated by FTIR, DLS, Zeta potential, and FESEM. Moreover, ultraviolet and visible absorption was revealed at 218 nm, ζ potential rate at -65.6 mV, and DLS values were recorded at (36.67–172.6) nm.. The polydispersity index value was ranged (0.369–0.663), indicating good monodispersity and stability. Also, an effective formulation showed inhibition activity of both LDH and CK enzymes at IC50 (86.359, 72.480) ppm, respectively. Conclusion: In vitro study of BLV 2 application opened new horizons aimed to use the drug more accessibility by targeting the muscles. New baclofen vesicular formulations containing nanoparticles have been developed and prescribed to improve the effectiveness of the drug.